IngredientesArginine alpha-ketoglutarate (AAKG) is a salt of the amino acid arginine and alpha-ketoglutaric acid. It is also known as arginine 2-oxoglutarate. The compound is commonly abbreviated as AAKG or A-AKG. Alternative systematic and trade names recorded in the literature include: L-Arginine Alpha-Ketoglutarate, L-Arginine AKG, Arginine 2-Oxoglutarate, and Alpha-Cétoglutarate de L-Arginine. Arginine alpha-ketoglutarate is formed when two arginine molecules combine with one molecule of alpha-ketoglutarate.
Arginine alpha-ketoglutarate is a modified version of the amino acid arginine; alpha-ketoglutarate is an intermediate compound in the series of reactions that produce energy for the body. AAKG is a compound made from the amino acid arginine and alpha-ketoglutarate, an intermediary in the metabolic process known as the citric acid cycle.
L-Arginine: In mammals, L-arginine is classified as a semiessential or conditionally essential amino acid, depending on the developmental stage and health status of the individual. It can be derived from proline or glutamate, with the ultimate synthetic step catalyzed by argininosuccinate lyase. As a functional amino acid, L-arginine serves not only as a building block of protein but also as an essential substrate for the synthesis of nitric oxide (NO), creatine, polyamines, homoarginine, and agmatine in mammals (including humans).
Alpha-Ketoglutarate: AKG is one of the metabolites of the tricarboxylic acid (TCA) cycle, also known as the Krebs cycle, and synthesized in the body. It plays a crucial role in cell energy metabolism, amino acid/protein synthesis, epigenetic regulation, stemness and differentiation. Glutamate dehydrogenase (GDH/GLUD1) catalyzes the production of glutamate from the tricarboxylic acid (TCA) cycle metabolite alpha-ketoglutarate (α-KG) and NH4+.
L-arginine is found in high concentration in foods like watermelon, nuts, seeds, algae, meats, seafood, beans, lentils, whole grains, rice protein concentrate, and soy protein isolate. L-arginine is synthesized in the body from citrulline. Alpha-ketoglutarate itself is an endogenous metabolite present in all living cells as a central intermediate of the Krebs cycle; AKG is also produced through oxidative deamination of glutamate and glutamine in cytosol.
AAKG as a specific salt is not found in nature as such — it is a synthetically produced compound formed by the ionic combination of L-arginine and alpha-ketoglutaric acid and is manufactured specifically for use in dietary supplements and clinical nutrition products.
AAKG is commercially available primarily as an oral dietary supplement. Subjects have been instructed to ingest four caplets of the supplements three times per day (12 caplets daily). Each 1.5-g caplet provided 0.5 g of L-arginine and 0.5 g of AKG in a 1:1 ratio; the remaining 0.5 g in each caplet contained time-release material and other excipients. Ingestion of 12 caplets/day therefore provided approximately 6 g of L-arginine and 6 g of AKG. The compound is also formulated as bulk powders for mixing in beverages, as well as in multi-ingredient pre-workout formulations. Both standard (non-time-released) and time-released caplet forms have been evaluated in clinical pharmacokinetic studies, with differing plasma arginine profiles documented between these two delivery forms.
The combination of alpha-ketoglutarate and arginine improves the stability of arginine. This is supposed to improve its performance-enhancing abilities and its role in energy production.
L-arginine and alpha-ketoglutarate as individual biochemical entities have long histories in both nutritional science and clinical medicine, although the specific salt AAKG is a relatively modern pharmaceutical and dietary supplement formulation without a traditional herbal medicine heritage.
Alpha-ketoglutarate salts as a class were incorporated into clinical nutrition protocols from at least the 1970s. Studies conducted in 1977 revealed the ability of arginine alpha-ketoglutarate to enhance hepatic detoxification capacity when administered in high dosage to patients with liver cirrhosis (Muting et al., 1977, MMW Munch Med Wochenschr, 119(16):535–8). Its effects were marked by a significant decrease in the level of plasma ammonia and free serum phenols, which indicated improved oxidative decomposition of these compounds.
A related compound, ornithine alpha-ketoglutarate (OKG), was employed in French clinical nutrition settings from the 1980s onward for burn patients and the critically ill, establishing much of the early scientific interest in alpha-ketoglutarate salts. OKG administration improves nutritional status in chronically malnourished (e.g., elderly) and acutely malnourished patients (especially burn and trauma patients). The clinical use of arginine-containing alpha-ketoglutarate salts in parenteral and enteral nutrition products therefore has its roots in academic hospital medicine rather than in folk or botanical tradition.
Previous studies demonstrated the potency of alpha-ketoglutarate in conserving endogenous glutamine pools and increasing glutamine synthesis, which have particular benefits in clinical nutrition and metabolic care by countering trauma-induced catabolism (Cynober, 1999, Curr Opin Clin Nutr Metab Care, 2(1):33–7).
The contemporary use of AAKG as a sports and bodybuilding supplement emerged in the late 1990s and early 2000s, primarily in North American and European fitness markets, following the popularization of nitric oxide as a concept in exercise physiology after the awarding of the Nobel Prize for Physiology or Medicine in 1998 to the discoverers of NO signaling. Arginine in combination with alpha-ketoglutarate has been mainly manufactured and marketed to athletes for its performance-enhancing potential.
L-arginine, a semi-essential amino acid, is metabolised in the cell to generate nitric oxide (NO) and L-citrulline via the enzyme nitric oxide synthase (NOS), or urea and L-ornithine via arginase activity. NO, a major vasodilator, increases blood flow to tissues. The endothelium-derived relaxing factor (EDRF) known as NO is derived from L-arginine by the action of endothelial nitric oxide synthase (eNOS). Production of adequate amounts of NO by vascular endothelial cells is essential to maintain normal blood pressure and prevent the development of hypertension.
An important caveat exists regarding arginine supplementation and NO production. Physiological concentrations of L-arginine in healthy individuals are enough to saturate endothelial NOS, which is approximately 3 μmol/L. Therefore, supplementary L-arginine should not promote increased enzyme activity; consequently, no further NO production should theoretically occur. However, there is evidence describing NO-mediated biological effects associated with L-arginine supplementation despite the fact that NOS is theoretically saturated with the physiological concentration of L-arginine — hence the condition known as the "L-arginine paradox."
Arginine is required to maintain the urea cycle in the active state to detoxify ammonia. NOS oxidatively degrades L-arginine into L-citrulline and nitric oxide (NO) while arginase hydrolyzes L-arginine to urea and L-ornithine. L-arginine plays a critical role in cytoplasmic and nuclear protein syntheses, the biosynthesis of other amino acids, creatine synthesis, and the urea cycle. In this essential biochemical pathway, urea is synthesized from arginine to enable the body to remove excess ammonia, which is toxic to cells. L-arginine is classified as a glucogenic amino acid because it can be metabolized into alpha-ketoglutarate (AKG) and enter the citric acid cycle.
AKG, as a key intermediate metabolite in the TCA cycle, not only contributes to skeletal muscle regeneration and inhibits muscle atrophy but is also associated with improved exercise performance. Alpha-ketoglutarate is an intermediate compound in the series of reactions that produce energy for the body. It is the source of the amino acids glutamate and glutamine. By virtue of its role in the amino acid synthesis pathway, alpha-ketoglutarate exerts strong regulatory control over protein metabolism.
Arginine also activates cellular mechanistic target of rapamycin (mTOR) and focal adhesion kinase cell signaling pathways in mammals, thereby stimulating protein synthesis, inhibiting autophagy and proteolysis, enhancing cell migration and wound healing, promoting spermatogenesis and sperm quality, improving conceptus survival and growth, and augmenting the production of milk proteins.
AKG supports muscle recovery by stimulating muscle satellite cells (MuSCs) and macrophage polarization, aiding muscle repair and reducing fibrosis. Additionally, AKG shows promise in preventing muscle atrophy by enhancing protein synthesis, inhibiting degradation pathways, and modulating inflammatory responses, making it relevant in conditions like sarcopenia, cachexia, and injury recovery.
Supplementing with AAKG can increase the levels of AKG in the body, promote energy production, and enhance amino acid utilization, thereby supporting basal metabolism and improving exercise performance. U.S. Patent No. 5,646,187 describes the utility of alpha-ketoglutarate in treating critically ill patients for improving protein synthesis capacity, preserving lean body mass and maintaining energy status in skeletal muscle. Similarly, WO 89/03688 discloses the use of alpha-ketoglutarate to increase glutamine content in postoperative patients.
Alpha-ketoglutarate also possesses antioxidative properties, as supported by studies on hydrogen peroxide (H2O2)-induced hemolysis of human erythrocytes. In the context of aging biology, AKG has emerged as a multifunctional metabolite with pleiotropic roles in cellular metabolism, redox homeostasis, and aging regulation. Functioning as both an endogenous metabolic hub and signaling molecule, AKG orchestrates nitrogen flux in amino acid metabolism, serves as a co-substrate for epigenetic regulators, and modulates mitochondrial function.
Alpha-ketoglutarate, a key metabolite in the TCA cycle, is reported to extend lifespan in worms and can significantly extend lifespan and healthspan in mice. AKG is involved in various fundamental processes, including central metabolism, collagen synthesis, and epigenetic regulation. AKG serves as an obligatory co-substrate for the family of dioxygenase enzymes — including TET demethylases and histone demethylases — that regulate DNA and histone methylation status, thereby influencing gene expression epigenetically.
Background claim: Arginine-alpha-ketoglutarate (AAKG) supplements are alleged to increase nitric oxide production, thereby resulting in vasodilation during resistance exercise.
Key long-term study (Campbell et al., 2006): The most-cited controlled study of AAKG as an isolated supplement was published in the journal Nutrition. Investigators evaluated the pharmacokinetics, safety, and efficacy of L-arginine alpha-ketoglutarate in trained adult men. Subjects participated in two studies that employed a randomized, double-blind, controlled design. In study 1, 10 healthy men (30–50 years old) fasted for 8 hours and then ingested 4 g of time-released or non-timed-released AAKG. In study 2, which was placebo controlled, 35 resistance-trained adult men (30–50 years old) were randomly assigned to ingest 4 g of AAKG (three times a day, i.e., 12 g daily, n=20) or placebo (n=15). Participants performed 4 days of periodized resistance training per week for 8 weeks. At 0, 4, and 8 weeks of supplementation, clinical blood markers, one repetition maximum bench press, isokinetic quadriceps muscle endurance, anaerobic power, and aerobic capacity were assessed. In study 1, significant differences were observed in plasma arginine levels between subjects taking non-timed-release and timed-release AAKG. In study 2, significant differences were observed in the AAKG group (P<0.05) for 1RM bench press, Wingate peak power, blood glucose, and plasma arginine. No significant differences were observed between groups in body composition, total body water, isokinetic quadriceps muscle endurance, or aerobic capacity. AAKG supplementation appeared to be safe and well tolerated, and positively influenced 1RM bench press and Wingate peak power performance. AAKG did not influence body composition or aerobic capacity.
Acute supplementation study (Wax et al., 2012, PMC): This study examined the efficacy of acute ingestion of L-arginine alpha-ketoglutarate (AAKG) on muscular strength and endurance in resistance trained and untrained men. Eight resistance trained and eight untrained healthy males ingested either 3000 mg of AAKG or a placebo 45 minutes prior to a resistance exercise protocol in a randomized, double-blind crossover design. The study found no significant acute benefit on measures of strength or muscular endurance. Like the Greer and Jones study, this study did not find an ergogenic effect on exercise performance variables following acute ingestion of AAKG. This may suggest that a specific loading period may be necessary for the prospective ergogenic effects of arginine-based supplements to be realized.
Muscle endurance and blood pressure study (Greer & Jones, 2011): The purpose of this study was to determine whether acute arginine alpha-ketoglutarate supplementation (AAKG) would affect local muscle endurance of the arm and shoulder girdle or the blood pressure (BP) response to anaerobic exercise. Twelve trained college-aged men (22.6 ± 3.8 years) performed 2 trials of exercise separated by at least 1 week. At 4 hours before, and 30 minutes before exercise, a serving of an AAKG supplement (3,700 mg arginine alpha-ketoglutarate per serving) or placebo was administered. AAKG supplementation did not improve muscle endurance or significantly affect the BP response to anaerobic work. Subjects performed fewer total chin-ups (23.75 ± 6.38 vs. 25.58 ± 7.18) and total trial repetitions (137.92 ± 28.18 vs. 141.08 ± 28.57) in the supplement trial (p ≤ 0.05). Subjects also executed fewer reverse chin-ups (5.83 ± 1.85 vs. 6.75 ± 2.09) during set 2 after receiving the supplement compared to placebo (p < 0.05).
Blood flow and nitric oxide study (Willoughby et al., 2011): This study sought to determine the effects of AAKG supplementation on hemodynamics and brachial-artery blood flow and the circulating levels of L-arginine, nitric oxide metabolites (NOx; nitrate/nitrite), asymmetric dimethyl arginine (ADMA), and L-arginine:ADMA ratio after resistance exercise. Twenty-four physically active men underwent 7 days of AAKG supplementation with 12 g/day of either NO2 Platinum or placebo. Before and after supplementation, a resistance-exercise session involving the elbow flexors was performed involving 3 sets of 15 repetitions with 70–75% of 1-repetition maximum. Heart rate, blood pressure, and blood flow were increased in both groups post-exercise (p = .001) but were not different between groups. Plasma L-arginine was increased in the NO2 group (p = .001). NOx was shown to increase in both groups post-exercise but was not different between groups. ADMA was not affected; however, the L-arginine:ADMA ratio was increased in the NO2 group (p = .03). AAKG increased plasma L-arginine levels; however, the effects observed in hemodynamics, brachial-artery blood flow, and NOx could only be attributed to the resistance exercise.
Overall evidence strength for exercise performance: Peer-reviewed studies have found no increase in muscle protein synthesis or improvement in muscle strength from use of AAKG as a dietary supplement. The weight of current evidence is mixed. One longer-term (8-week) randomized controlled trial showed statistically significant but modest improvements in bench press 1RM and anaerobic peak power, while multiple acute-administration trials have found no performance benefit. The discrepancy between long-term and acute findings suggests that if benefits exist, they require a prolonged supplementation period. The evidence base is limited by small sample sizes, predominantly male populations, and the fact that most trials tested AAKG within multi-ingredient products rather than as an isolated ingredient.
Studies conducted in 1977 revealed AAKG's ability to enhance hepatic detoxification capacity when administered in high dosage to patients with liver cirrhosis, with effects marked by a significant decrease in the level of plasma ammonia and free serum phenols. Administration of arginine and alpha-ketoglutarate has also proven useful in treating ammonia intoxication and heightening liver detoxification in animal models. The survival rate was found to be higher in the treatment group relative to the control, and the treatment group also suffered fewer convulsive episodes. These are early and non-replication findings; the ammonia-detoxification evidence has been explored more extensively with the related compound ornithine alpha-ketoglutarate (OKG) than with AAKG specifically.
The most robust clinical evidence involving alpha-ketoglutarate salts in critical care pertains to ornithine alpha-ketoglutarate (OKG) rather than AAKG directly. However, preclinical work directly comparing the two compounds has been conducted. Enteral administration of ornithine alpha-ketoglutarate versus arginine alpha-ketoglutarate in burn-injured rats was compared to evaluate their effects on glutamine pools.
For OKG (a closely related alpha-ketoglutarate salt), a prospective randomized double-blind study demonstrated meaningful outcomes in severe burn patients: In this study, 60 patients who had undergone severe burns (20–60% of body surface area) received either ornithine alpha-ketoglutarate (20 g/day) or an isocaloric placebo for 21 days, starting a mean of 4 days after injury. In the OKG group, nitrogen balance reached positive values at day 5 and stabilized at higher levels versus controls (P < 0.05 or less from day 3 to day 21), resulting in a strongly positive cumulated nitrogen balance at day 21. Transthyretin and RBP levels were higher in the OKG group. Body weight loss was counteracted at day 21 in the OKG group (−2.6% vs −6.3%, P < 0.001). Assessment of the quality of wound healing using objective scoring showed better performances in the OKG group (P < 0.05). These OKG findings are not directly transferable to AAKG, as the two salts differ in their amino acid composition and metabolic fates, but they demonstrate the potential of alpha-ketoglutarate-based salts in hyper-catabolic states.
Alpha-ketoglutarate has demonstrated potency in conserving endogenous glutamine pools and increasing glutamine synthesis, which have particular benefits in clinical nutrition and metabolic care by countering trauma-induced catabolism. U.S. Patent No. 5,646,187 describes the utility of alpha-ketoglutarate in treating critically ill patients for improving protein synthesis capacity, preserving lean body mass and maintaining energy status in skeletal muscle. WO 89/03688 discloses the use of alpha-ketoglutarate to increase glutamine content in postoperative patients.
Nitric oxide (NO) is derived from L-arginine by the action of endothelial nitric oxide synthase (eNOS). Production of adequate amounts of NO by vascular endothelial cells is essential to maintain normal blood pressure and prevent the development of hypertension. There is broader evidence from L-arginine supplementation research suggesting a blood pressure-lowering potential, though specific AAKG trials have not demonstrated that the hemodynamic effects observed in exercising subjects are attributable to the supplement rather than exercise itself. As documented in Willoughby et al. (2011), AAKG increased plasma L-arginine levels; however, the effects observed in hemodynamics, brachial-artery blood flow, and NOx could only be attributed to the resistance exercise.
Significant research interest has emerged around the longevity-relevant properties of alpha-ketoglutarate, though this evidence pertains primarily to AKG rather than specifically to the AAKG salt.
The tricarboxylic acid (TCA) cycle intermediate alpha-ketoglutarate (alpha-KG) extends the lifespan of adult C. elegans. ATP synthase subunit beta was identified as a novel binding protein of alpha-KG using a small-molecule target identification strategy. The TCA cycle intermediate alpha-KG delays ageing and extends the lifespan of C. elegans by approximately 50%.
In mouse studies, alpha-ketoglutarate (delivered in the form of a calcium salt, CaAKG), a key metabolite in the TCA cycle that is reported to extend lifespan in worms, can significantly extend lifespan and healthspan in mice.
Alpha-ketoglutarate (AKG) has been introduced as a potential anti-aging metabolite that can control several functions in organisms, thereby increasing longevity and improving healthspan.
Human research on AKG is still limited, but a small number of early studies have produced findings worth noting. Some human studies have examined calcium AKG in relation to biological age markers, including DNA methylation. These studies reported reductions in biological aging markers over relatively short periods. These early findings are encouraging, but they should be interpreted with care. The longevity evidence for AAKG specifically, as opposed to other AKG salts (especially calcium AKG), is not well established in human trials.
Research in animal models has documented potential effects of AKG on bone: administration of alpha-KG increases the bone mass of aged mice, attenuates age-related bone loss, and accelerates bone regeneration of aged rodents. Alpha-KG ameliorates the senescence-associated phenotypes of bone marrow mesenchymal stromal/stem cells derived from aged mice, as well as promoting their proliferation, colony formation, migration, and osteogenic potential. Mechanistically, alpha-KG decreases the accumulations of H3K9me3 and H3K27me3, and subsequently upregulates BMP signaling and Nanog expression. These findings are from animal models; direct human clinical evidence for AAKG and bone health is currently absent.
A preclinical investigation in diet-induced obese rats examined the effects of AKG on NO synthesis and insulin sensitivity: L-leucine inhibits the synthesis of nitric oxide from L-arginine by endothelial cells, contributing to impairments in angiogenesis, blood flow, and vascular dysfunction, as well as insulin resistance. Reduction in the circulating levels of branched-chain amino acids through dietary supplementation with alpha-ketoglutarate to promote their transamination in the small intestine and other tissues can restore nitric oxide synthesis in the vasculature and reduce the weights of white adipose tissues, thereby improving metabolic profiles and whole-body insulin sensitivity in diet-induced obese rats. This is animal-model evidence only; no equivalent human trials for AAKG in metabolic syndrome have been identified in the peer-reviewed literature.
The following dosages are drawn exclusively from published clinical studies and regulatory assessment documents, and reflect doses tested in those contexts only.
Across controlled studies, oral AAKG doses specifically have ranged from approximately 3 g to 12 g per day. No consensus or regulatory-approved standard dosage currently exists for AAKG as a dietary supplement.
AAKG supplementation in the Campbell et al. (2006) study appeared to be safe and well tolerated. However, adverse cardiovascular events have been reported in case series associated with AAKG-containing products. Prosser et al. (2009) published a report in Human and Experimental Toxicology describing three emergency department presentations:
Three patients presented to the emergency department with adverse effects. A 33-year-old man presented with palpitations, dizziness, vomiting, and syncope after the use of NO2 Platinum. His examination and electrocardiogram (ECG) were normal. The dizziness persisted, requiring admission overnight. A 21-year-old man with palpitations and near syncope had used a "nitric oxide" supplement. He was tachycardic to 115 bpm with otherwise normal examination. Laboratory values including methemoglobin, and ECG were unremarkable. He was treated with 1 L of saline with no change in heart rate. A 24-year-old man presented after taking NO-Xplode with palpitations and a headache. His examination, laboratory values, and ECG were normal.
The purported active ingredient in these products is arginine alpha-ketoglutarate (AAKG), which is claimed to increase NO production by supplying the precursor L-arginine. The symptoms could be due to vasodilation from increased levels of NO, though other etiologies cannot be excluded. AAKG-containing supplements may be associated with adverse effects requiring hospital admission.
It is important to note that these products were multi-ingredient formulations; causal attribution to AAKG specifically cannot be confirmed from these case reports.
In a randomized, placebo-controlled, double-blind trial of healthy men, 21 g/day of oral L-arginine increased plasma arginine concentration and impaired platelet aggregation in subjects treated with L-arginine. However, there was no difference in hemodynamic variables or nitrosoprotein concentrations (used as a surrogate measure for NO). This finding pertains to L-arginine itself at high doses and is relevant to AAKG as a source of arginine.
A risk assessment of L-arginine and L-arginine alpha-ketoglutarate (AAKG) was conducted based on published articles and previous risk assessments of L-arginine, noting that L-arginine is an ingredient in food supplements sold in Norway. Due to the lack of adequate scientific information, a no observed adverse effect level (NOAEL) has not been firmly established.
Physiological concentrations of L-arginine in healthy individuals are enough to saturate endothelial NOS, which is approximately 3 μmol/L. Therefore, supplementary L-arginine theoretically should not promote increased enzyme activity, and no further NO production should occur. This biochemical consideration limits the mechanistic rationale for AAKG's proposed vasodilatory effects in healthy individuals with normal arginine status.
Based on the pharmacology of its constituent molecules:
The interactions between alpha-ketoglutarate and medicines are not fully understood. As with most dietary supplements, the research on drug interactions with alpha-ketoglutarate is incomplete.
Gastrointestinal discomfort, including nausea and diarrhea, is associated with high-dose arginine supplementation in general, consistent with findings for other amino acid supplements taken in large quantities. This has been documented more specifically for ornithine alpha-ketoglutarate at doses over 5–10 g.
Supplementation may be needed and is more clinically relevant in special conditions such as malnutrition, excessive ammonia production, burns, infections, peritoneal dialysis, rapid growth, urea synthesis disorders, and/or sepsis. In these populations, however, AAKG is typically used under medical supervision rather than as a self-directed dietary supplement.
Condiciones de salud que arginina alfa cetoglutarato puede ayudar a apoyar.
Alpha-ketoglutarate possesses direct antioxidant properties, including protection against hydrogen-peroxide-induced oxidative damage in human erythrocytes, and reduces GSSG/GSH ratios in tissues. AKG's antioxidant and nitrogen-scavenging roles are documented in both in vitro and animal studies.
Arginine alpha-ketoglutarate (AAKG) combines L-arginine with AKG to potentially enhance nitric oxide production and ergogenic effects. Select RCTs show improvements in 1RM bench press and anaerobic power. It is commonly used as a pre-workout ergogenic aid and is listed as a proposed performance supplement in sports medicine databases.
L-arginine, the primary component of AAKG, is an established precursor for vascular NO, and meta-analyses of L-arginine RCTs report modest blood-pressure-lowering effects. AAKG-specific BP data are sparse; studies show plasma arginine rises substantially with AAKG but independent BP reduction beyond exercise effects has not been isolated.
Alpha-ketoglutarate is a central intermediate of the TCA (Krebs) cycle, directly participating in ATP generation via oxidative decarboxylation to succinyl-CoA. AAKG thus provides a direct metabolic precursor for mitochondrial energy production, and this is characterized as a fundamental biological role.
AAKG is a precursor to nitric oxide (NO), a key vasodilatory signaling molecule. Clinical studies confirm AAKG significantly raises plasma L-arginine levels, though observed improvements in brachial-artery blood flow in exercise contexts appear attributable to exercise itself rather than the supplement independently. The L-arginine component still underpins a plausible and studied vascular mechanism.
The arginine component of AAKG is a precursor to NO in penile vascular tissue, and L-arginine RCTs show modest benefit in mild-to-moderate erectile dysfunction. Direct AAKG-specific evidence is very limited, with most data extrapolated from L-arginine trials; combining AAKG with PDE5 inhibitors has been proposed as additive.
L-arginine is a well-established stimulant of pituitary growth hormone secretion, acting by suppressing endogenous somatostatin. AAKG's arginine moiety shares this property; acute arginine supplementation has been shown in RCTs to modestly increase GH levels. A 2022 systematic review and meta-analysis confirmed significant GH release with arginine supplementation alone.
The alpha-ketoglutarate (AKG) component of AAKG is a TCA-cycle intermediate whose endogenous levels decline with age. Preclinical studies (mice) demonstrate AKG extends healthspan and reduces chronic inflammatory cytokines. Early human observational data suggest improvements in biological aging markers; formal RCTs in humans are underway but limited.
L-arginine improves insulin sensitivity via NO-mediated enhancement of glucose transporter activity, and several preclinical and clinical studies support this in obese and type 2 diabetic patients. The AKG moiety independently reduces plasma glucose, triacylglycerols, and BCAA concentrations through distinct metabolic pathways.
The AKG component of AAKG supports muscle recovery by stimulating muscle satellite cells, enhancing protein synthesis, and inhibiting catabolic pathways. A 2024 narrative review of 112 peer-reviewed articles confirms AKG's role in counteracting muscle atrophy and supporting post-exercise recovery.
Arginine alpha-ketoglutarate (AAKG) is a salt of L-arginine and alpha-ketoglutaric acid used to deliver arginine as a NO precursor. A 7-day RCT showed AAKG significantly raised plasma L-arginine by ~85% but did not produce greater post-exercise NO or blood flow increases than placebo, indicating the arginine component drives any NO effect while independent benefit of the salt form is limited.
AAKG is widely used as a pre-workout supplement, with the arginine moiety intended to enhance NO-mediated oxygen delivery to muscles. The 8-week Campbell et al. RCT found AAKG improved Wingate peak power in resistance-trained men, and the AKG narrative review confirms AKG supplementation can enhance endurance and reduce fatigue.
Alpha-ketoglutarate salts (particularly ornithine-AKG) have documented human clinical evidence for reducing post-surgical catabolism, preserving lean mass, and improving protein synthesis after major surgery. The AKG moiety's glutamine-sparing and anti-catabolic effects are shared by AAKG. Early 1980s–1990s clinical studies established this evidence base.
Supplemental arginine enhances collagen synthesis, a key component of wound healing, and alpha-ketoglutarate salts have direct RCT evidence in burn patients. A prospective, double-blind RCT with OKG (a structurally related AKG salt) in 60 severely burned patients showed significantly better wound healing scores, nitrogen balance, and reduced body weight loss.
Sistemas corporales que arginina alfa cetoglutarato puede ayudar a apoyar.
Volver